Abstract 1494P
Background
Furoquitinib(F) is an orally highly selective tyrosine kinase inhibitor targeting VEGFR1,2,3. We previously reported some results of NCT04956146, which demonstrated that F plus PD-1 inhibitor sintilimab(S) and platinum-based chemotherapy(chemo) had encouraging efficacy and manageable toxicity as the first-line treatment for advanced naive EGFR- and ALK-negative nsq-NSCLC. Herein, we present updated results.
Methods
This single-arm, open-label, phase Ⅱ study consists of a safety lead-in phase (Part 1) and dose expansion phase (Part 2). In Part 1 the F taken orally at 5 mg (2 weeks on/ 1 weeks off, Q3W) plus S (200mg, iv, d1,Q3W) and chemo(Q3W). After 4∼6 cycles followed by maintenance therapy with F(RP2D) plus S and pemetrexed or not. DLT was observed for 1 cycle. The primary objective of Part 1 is to assess the safety and confirm the RP2D of F. The primary objective of Part 2 is to estimate the PFS and the secondary endpoints including ORR, DCR, OS, and safety.
Results
From February 2022 to May 2023, 26 pts were enrolled. The median age was 62 years, with males 92.3%, ECOG PS 0 73.1%, and the median sum of longest diameters (SLD) is 100.805mm. Pts with PD-L1 TPS ≥1%, <1%, and unknown were 14, 8, and 4 respectively. Of 20 evaluable pts, ORR and DCR were 80% and 100%. According to PD-L1 level, ORR was 91.7% and 57.1% for pts with PD-L1 TPS ≥1% and <1%. ORR was 60% for baseline SLD<median SLD and 100% for median SLD>median SLD. Median PFS was not reached yet. All pts experienced≥1 treatment-emergent adverse events (TEAEs). The most common Gr≥3 TEAEs (≥10% pts) were Neutrophil count decreased (42.3%), Anaemia(15.4%), Gamma-glutamyltransferase increased(11.5%) and hypertriglyceridaemia (11.5%).
Conclusions
This finding showed promising efficacy for fruquintinib combined with sintilimab and chemo in pts with advanced NSCLC as a first-line treatment with a manageable safety profile. This study might represent a potential treatment option for pts with unresectable or metastatic advanced naive EGFR- and ALK-negative nsq-NSCLC.
Clinical trial identification
NCT04956146; Release date: February 2, 2022.
Editorial acknowledgement
Legal entity responsible for the study
The First Affiliated Hospital with Nanjing Medical University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1499P - Wnt5-ROR2 signalling mediated resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer
Presenter: Etienne Giroux-Leprieur
Session: Poster session 21
1500TiP - REFINE-Lung is a multicentre phase III study to determine the optimal frequency of pembrolizumab in non-small cell lung cancer utilising a novel multi-arm design
Presenter: Ehsan Ghorani
Session: Poster session 21
1502TiP - A phase I/IIa trial of ChAdOx1 and MVA vaccines against MAGE-A3 and NY-ESO-1
Presenter: Fiona Blackhall
Session: Poster session 21
1503TiP - A phase II study of cemiplimab plus BNT116 versus cemiplimab alone in first-line treatment of patients with advanced non-small cell lung cancer with PD-L1 expression ≥50%
Presenter: Mark Awad
Session: Poster session 21
1504TiP - HARMONi: Randomized, double-blind, multi-center, phase III clinical study of ivonescimab or placebo combined with pemetrexed and carboplatin in patients with EGFR-mutant locally advanced or metastatic non-squamous NSCLC who have progression following EGFR-TKI treatment
Presenter: WenFeng Fang
Session: Poster session 21
1505TiP - TROPION-Lung07: A phase III trial of datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy in advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) with PD-L1 expression
Presenter: Isamu Okamoto
Session: Poster session 21
1506TiP - A single-arm, phase II study of amivantamab (AMI), lazertinib (L) and pemetrexed (P) for first-line treatment of recurrent/metastatic non-small cell lung cancers (NSCLCS) with epidermal growth factor receptor mutations in Exons 19 or 21 (EGFR 19/21): AMIGO 1 (LACOG0821)
Presenter: William Nassib William Junior
Session: Poster session 21
1507TiP - Phase Ib multicenter study of trastuzumab deruxtecan (T-DXd) and immunotherapy with or without chemotherapy in first-line treatment of patients (pts) with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (OE): DESTINY-Lung03
Presenter: David Planchard
Session: Poster session 21
1508TiP - The 1920-EORTC-BIORADON study: Molecular characterization of non-small cell lung cancer (NSCLC) and indoor radon exposure in Europe
Presenter: Laura Mezquita
Session: Poster session 21